U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -0.32 (-0.61%)
     
  • Gold

    1,827.70
    -2.20 (-0.12%)
     
  • Silver

    24.83
    -0.04 (-0.14%)
     
  • EUR/USD

    1.2074
    -0.0081 (-0.66%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3601
    -0.0091 (-0.66%)
     
  • USD/JPY

    103.7600
    -0.0560 (-0.05%)
     
  • BTC-USD

    36,613.38
    +1,612.71 (+4.61%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LRN, YY and NERV

·3 min read

NEW YORK, NY / ACCESSWIRE / December 29, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

K12 Inc. (NYSE:LRN)
Class Period: April 27, 2020 - September 18, 2020
Lead Plaintiff Deadline: January 19, 2021

Throughout the class period, K12 Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.

Learn about your recoverable losses in LRN: http://www.kleinstocklaw.com/pslra-1/k12inc-loss-submission-form?id=11838&from=1

Joyy Inc. (NASDAQ:YY)
Class Period: April 28, 2016 - November 18, 2020
Lead Plaintiff Deadline: January 19, 2021

The YY lawsuit alleges Joyy Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.

Learn about your recoverable losses in YY: http://www.kleinstocklaw.com/pslra-1/joyy-inc-loss-submission-form?id=11838&from=1

Minerva Neurosciences, Inc. (NASDAQ:NERV)
Class Period: May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline: February 8, 2021

During the class period, Minerva Neurosciences, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=11838&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/622520/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-LRN-YY-and-NERV